Papilloma virus, a new vaccine with a strong response is being studied. The new vaccine based on recombinant Omvs promises a strong neutralizing response with a high spectrum of action.
The HPV vaccines currently on the market are based on the L1 protein. In order to overcome these limitations, the researchers of the Vaccibiome team have developed a vaccine based. on the use of portions of the L2 protein of HPV which is much more conserved between the various serotypes than L1.